Life sciences VC firm Abingworth has held a final close on $315m for Abingworth Bioventures VII (ABV VII), surpassing its $300m target.
Renaud Tourmente will join as partner and be part of Capzanine's executive committee
Hitzinger was undergoing self-administration before the consortium acquired the company
Graftys sells products in 25 countries and plans to penetrate new markets with the funding
US pension has targeted $80m for new private markets commitments through the rest of 2019